Skip to Main Content

Author Details

George V Thomas
Knight Cancer Institute, Oregon Health and Science University
2016
19
11
PMIDPaper TitleJournal TitlePublished Year
35322234Androgen receptor activity in T cells limits checkpoint blockade efficacy.Nature2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
33414172Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth.Cancer Res2021
33772089Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics.NPJ Precis Oncol2021
34911933Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.Nat Commun2021
34095877Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.Cell Rep Med2021
31155953Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.Nutr Cancer2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
32616555A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.J Immunother Cancer2020
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
30928160Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
31565603Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.Cureus2019
30804427MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2019
30918106Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.Mol Cancer Res2019
31035489Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma.Metabolites2019
30269481Proteome Profiling of 1 to 5 Spiked Circulating Tumor Cells Isolated from Whole Blood Using Immunodensity Enrichment, Laser Capture Microdissection, Nanodroplet Sample Processing, and Ultrasensitive nanoLC-MS.Anal Chem2018
31650098Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.JCO Precis Oncol2017
27694829Systemic Inhibition of CREB is Well-tolerated in vivo.Sci Rep2016
  • 1 - 19 of 19

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 4
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 3
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 6
Alexandra Corella
Fred Hutchinson Cancer Research Center
Career Start Year 2015
Number of shared co-authors 4
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 5
Anjali V Sheahan
Dana-Farber Cancer Institute
Career Start Year 2012
Number of shared co-authors 6
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 20
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 29
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 7
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 16
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 0
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 6
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 7
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 4
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 8
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 6
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 7
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 3
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 27
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 7
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 13
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 14
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Amina Zoubeidi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 24
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 7
Johann S de Bono
The Institute for Cancer Research
Career Start Year 1999
Number of shared co-authors 17
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 14
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 22
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 21
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 27

Collaborators

Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 11
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 9
Eric J Small
University of California san francisco
Co-authored papers 8
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 7
Rahul Aggarwal
University of California San Francisco
Co-authored papers 7
Adam Foye
University of California San Francisco
Co-authored papers 7
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 7
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 7
Martin E Gleave
University of British Columbia
Co-authored papers 7
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 6
Christopher P Evans
University of California Davis
Co-authored papers 6
David A Quigley
University of California-San Francisco
Co-authored papers 6
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 5
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 5
Alana S Weinstein
University of California San Francisco
Co-authored papers 4
Kim N Chi
University of British Columbia
Co-authored papers 3
Owen N Witte
University of California los angeles
Co-authored papers 3
Eric Lu
David Geffen School of Medicine at university of california los angeles
Co-authored papers 3
Laura M Heiser
Oregon Health Sciences University
Co-authored papers 2
Joshua Urrutia
Knight Cancer Institute, Oregon Health & Science University (OHSU)
Co-authored papers 2
Christopher K Wong
University of California
Co-authored papers 2
Mary A Wood
Phase Genomics Inc.
Co-authored papers 2
Christopher L Corless
Oregon Health & Science University
Co-authored papers 2
Reid F Thompson
Oregon Health and Sciences University
Co-authored papers 2
Vladislav Uzunangelov
University of California
Co-authored papers 2
Paul Lloyd
Bluestar Genomics Inc.
Co-authored papers 2
Yuzhuo Wang
University of British Columbia
Co-authored papers 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 1
Matthew M Abelman
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Anthony B Pinkerton
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Release 1.2